Renata Enters Canadian Market with Oral Contraceptive Launch

Date:

Post View:

Renata Enters Canadian Market with Oral Contraceptive Launch

Toronto, Canada – Renata PLC has officially entered the Canadian pharmaceutical market with the launch of its first product: Desogestrel/Ethinylestradiol (0.15mg/0.03mg) oral contraceptive tablets.

The product, a fixed-dose combination of Desogestrel (a progestin) and Ethinylestradiol (an estrogen), is being introduced under the brand names Miley 21 and Miley 28. It will be commercialised through a strategic partnership with Ambicare Pharmaceuticals Inc., a Canadian company known for its portfolio of high-quality, niche generic products across multiple therapeutic areas.

The tablets are manufactured at Renata’s Health Canada-approved potent product facility, ensuring compliance with stringent quality and regulatory standards.

Renata also markets the same formulation in Bangladesh under the brand name Desolon.

This marks a significant milestone for Renata as it expands into North America, with plans to grow its product portfolio in the Canadian market.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Share post:

Subscribe

spot_img

Popular

More like this
Related

Undermining Local Spinning in Favour of Imports: At What Cost?

S H Fahim: Bangladesh's debate over bonded warehouse facilities...

Leadership Development Training held at Al-Arafah Islami Bank

A day-long training programme titled “Connect, Influence & Grow:...

Southeast Bank signs MoU with Fair Technology to promote Hyundai vehicles

Southeast Bank PLC. has signed a Memorandum of Understanding...

Women entrepreneurs receive only 7.5pc of CMSME loans

Women-owned businesses received only 7.5 per cent of total...